152 related articles for article (PubMed ID: 22052279)
1. Pigmentary changes in a patient treated with imatinib.
Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
[TBL] [Abstract][Full Text] [Related]
2. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
4. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Alexandrescu DT; Dasanu CA; Farzanmehr H; Kauffman L
Dermatol Online J; 2008 Jul; 14(7):7. PubMed ID: 18718191
[TBL] [Abstract][Full Text] [Related]
5. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
Gulati AP; Saif MW
Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
7. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
[TBL] [Abstract][Full Text] [Related]
8. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
9. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
10. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
11. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
13. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
14. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
15. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
[TBL] [Abstract][Full Text] [Related]
16. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
19. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
20. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
